Covid-19 and Bronchial Asthma (Clinical and Epidemiological Aspects)

  • Nigmatullayeva M. A. Bukhara State Medical Institute, Uzbekistan
  • Navro’zova O’. O Bukhara State Medical Institute, Uzbekistan
Keywords: coronavirus infection, coronavirus, COVID-19, bronchial asthma, pandemic

Abstract

The review article combines modern knowledge about the origin, pathogenesis, epidemiology, clinical and laboratory diagnostics, as well as therapy and prevention of new coronavirus infection; describes the possible relationship of coronavirus infection with bronchial asthma, as well as possible options for the effect of coronavirus infection on the severity of bronchial asthma collected from publications of specialists of the Russian Federation and researchers from various countries.

References

1. World Health Organization. Asthma [Internet]. Geneva: WHO; 2020. Accessed October 20, 2020.https://www.who.int/ru/news-room/fact-sheets/detail/asthma
2. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004;59(5):469-478. https://doi.org/10.1111/j.1398-9995.2004.00526.x
3. Diagnosing asthma: a 21st century challenge. Accessed June 03, 2020.https://www.asthma.org.uk/a54e6a69/globalassets/get-involved/external-affairscampaigns/diagnostics/diagnosing-asthma-21st-century-challenge.pdf
4. Du Toit A. Outbreak of a novel coronavirus // Nat. Rev. Microbiol.2020. Vol. 18, N 3.Р. 123.
5. Wang W., Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China // J. Med. Virol.2020. Vol. 92, N 4. Р. 441–447.
6. URL: https://www.ncbi.nlm.nih.gov/pubmed
7. URL:http://viro-logical.org/t/novel-2019-coronavirus-genome/319;Wuhan-Hu-1,GenBank accessionNo.MN908947.
8. WHO Coronavirus disease (COVID-19) outbreak. URL: https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
9. Abrams E. M., Greenhawt M. Risk communication during COVID-19 //J. Allergy Clin. Immunol. Pract. – 2020. – Vol. 8, № 6. ‒ Р. 1791-1794. DOI:10.1016/j.jaip.2020.04.012.
10. Abrams E. M., Szefler S. J. Managing asthma during coronavirus disease-2019:an example for other chronic conditions in children and adolescents //J. Pediatr. – 2020. – Vol. 222. – Р. 221-226. DOI: 10.1016/j.jpeds.2020.04.049.
11. Amirav I., Newhouse M. T. Transmission of coronavirus by nebulizer: a serious, underappreciated risk // CMAJ. – 2020. – Vol. 192, № 13. – Е346. DOI:10.1503/cmaj.75066.
12. Arabi Y. M., Mandourah Y., Al-Hameed F. et al. Corticosteroid the rapy for critically ill patients with Middle East respiratory syndrome // Am.J. Respir. Crit. Care Med. – 2018. – Vol. 197, № 6. – Р. 757-767. DOI:10.1164/rccm.201706-1172OC.
13. Ari A. Promoting safe and effective use of aerosol devices in COVID-19: risksand suggestions for viral transmission // Expert. Opin.Drug.Deliv. – 2020. –Vol. 17, № 11. – Р. 1509-1513. DOI: 10.1080/17425247.2020.1811225.
14. Avdeev S., Moiseev S., Brovko M. et al. Low prevalence of bronchial asthma and chronic obstructive lung disease among intensive care unit patients with COVID-19 // Allergy. ‒ 2020.‒ Vol. 75, № 10.‒ Р. 2703-2704. DOI:10.1111/all.14420.
15. Bhatraju P. K., Ghassemieh B. J., Nichols M. et al. Covid-19 in critically ill patients in the Seattle region ‒ Case series // N. Engl. J. Med. – 2020. – Vol. 382,№ 21. – Р. 2012-2022. DOI:10.1056/nejmoa2004500.
16. Bousquet J., Bergmann K. C., Zuberbier T., Bedbrook A., Onorato G. L., Jutel M.,Akdis C. A., Akdis M., Klimek L., Pfaar O., Nadeau K. C., Chinthrajah S.,Eiwegger T., Ansotegui I. J., Anto J. M., Bachert C., Bateman E. D., Bennoor K. S.,Berghea E. C., Blain H. et al. ARIA-EAACI statement on Asthma andCOVID-19 (JUNE 2, 2020) // Allergy. ‒ 2021.‒ Vol. 76, № 3. ‒ Р. 689-697.DOI: 10.1111/all.14471.
17. Bozek A., Winterstein J. Montelukast’s ability to fight COVID-19 infection //J. Asthma. – 2020. – Р. 1-2. DOI:10.1080/02770903.2020.1786112.
18. Brough H. A., Kalayci O., Sediva A. et al. Managing childhood allergies н Х immunodeficiencies during respiratory virus epidemics ‒ The 2020COVID-19 pandemic: a statement from the EAACI-section onpediatrics // Pediatr. Allergy Immunol. – 2020. – Vol. 31, № 5. – Р. 442-448.DOI:10.1111/pai.13262.
19. Chen N., Zhou M., Dong X. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China:a descriptive study // Lancet. – 2020. – Vol. 15, № 395. – Р. 507-513. DOI:10.1016/S0140-6736(20)30211-7.
20. Chhiba K. D., Patel G. B., Vu T. H. T. et al. Prevalence and characterization of asthma in hospitalized and no hospitalized patients with COVID-19 //J. Allergy Clin. Immunol. – 2020. – Vol. 146, № 2. – Р. 307-314.e4. DOI:10.1016/j.jaci.2020.06.010.
21. Chongmelaxme B., Lee S., Dhippayom T. et al. The effects of telemedicine on asthma control and patients’ quality of life in adults: a systematic review and meta-analysis // J. Allergy Clin. Immunol. Pract. – 2019. – Vol. 7, № 1. –Р. 199-216.e11. DOI: 10.1016/j.jaip.2018.07.015.
22. Chow N., Fleming-Dutra K., Gierke R. et al. Preliminary estimates of the prevalence of selected underlying health conditions among patientswith coronavirus disease 2019 ‒ United States, February 12 March 28,2020 // MMWR Morb Mortal Wkly Rep. – 2020. – Vol. 69, № 13. – Р. 382-386.DOI:10.15585/mmwr.mm6913e2.
23. Crimi C., Impellizzeri P., Campisi R. et al. Practical considerations for spirometryduring the COVID-19 outbreak: literature review and insights // Pulmonology. –2020. – S2531-0437(20)30175-6. DOI: 10.1016/j.pulmoe.2020.07.011.
24. Dempsey O. Leukotriene receptor antagonist therapy // Postgrad Med. J. –2000. – Vol. 76, № 902. – Р. 767-773.DOI :10.1136/pgmj.76.902.767.
25. Docherty A. B., Harrison E. M., Green C. A. et al. Features of 20 133 UK patientsin hospital with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort // BMJ. – 2020. – Vol. 369. m1985.DOI:10.1136/bmj.m1985.
26. Dong X., Cao Y. Y., Lu X. X. et al. Eleven faces of coronavirus disease 2019 //Allergy. – 2020. – Vol. 75, № 7. – Р. 1699-1709. DOI: 10.1111/all.14289.
27. Drummond M. Sleep labs, lung function tests and COVID-19 pandemic–only emergencies allowed! // Pulmonology. – 2020. – Vol. 26, № 4. – Р. 244-245. DOI:10.1016/j.pulmoe.2020.04.002.
28. Du Y., Tu L., Zhu P. et al. Clinical features of 85 fatal cases of COVID-19 fromWuhan. A retrospective observational study // Am. J. Respir. Crit. Care Med. –2020. – Vol. 201, № 11. – Р. 1372-1379. DOI: 10.1164/rccm.202003-0543OC.
29. Esquivel A., Busse W. W., Calatroni A. et al. Effects of omalizumab on rhinovirus infections, illnesses, and exacerbations of asthma // Am. J. Respir. Crit. CareMed. – 2017. – Vol. 196, № 8. – Р. 985-992. DOI: 10.1164/rccm.201701-0120OC.
30. Ferastraoaru D., Hudes G., Jerschow E. et al. Eosinophilia in asthma patientsis protective against severe COVID-19 illness // J. Allergy Clin. Immunol.Pract. – 2021. – Vol. 9, № 3. – Р. 1152-1162.e3. DOI: 10.1016/j.jaip.2020.12.045.
31. Garg S., Kim L., Whitaker M. et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease2019-COVID-NET, 14 States, March 1-30, 2020 // MMWR Morb Mortal WklyRep. – 2020. – Vol. 69, № 15. – Р. 458-464. DOI:1 0.15585/mmwr.mm6915e3.
32. Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2020.https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf(Accessed March 23, 2021).
33. Gosens R., Gross N. The mode of action of anticholinergics in asthma // Eur.Respir. J. – 2018. – Vol. 52, № 4. – Р. 701247. DOI: 10.1183/13993003.01247-2017.
34. Grandbastien M., Piotin A., Godet J. et al. SARS-CoV-2 pneumonia in hospitalized asthmatic patients did not induce severe exacerbation //J. Allergy Clin. Immunol. Pract. – 2020. – Vol. 8, № 8. – Р. 2600–2607. DOI:10.1016/j.jaip.2020.06.032.
35. Guan W. J., Ni Z. Y., Hu Y. et al. Clinical characteristics of coronavirus disease2019 in China // N. Engl. J. Med. – 2020. – Vol. 382, № 18. – Р. 1708-1720. DOI:10.1056/NEJMoa2002032.
36. Halpin D. M, Singh D., Hadfield R. M. et.al. Inhaled corticosteroids andCOVID-19: a systematic review and clinical perspective // Eur. Respir. Soc. –2020. – Vol. 55, № 5. – Р. 2001009. DOI: 10.1183/13993003.01009-2020.
37. Interim guidance about COVID-19 and asthma. Updated 20 Dec 2020.https://ginasthma.org/wp-content/uploads/2020/12/GINA-interim-guidance-on-COVID-19-and-asthma-20_12_20.pdf(Accessed March 20, 2021).
38. Iwabuchi K., Yoshie K., Kurakami Y. et.al. Therapeutic potential of cicles on ide inhalation for COVID-19 pneumonia: Report of three cases // J. Infect. Chemother. – 2020. – Vol. 26, № 6. – Р. 625-632. DOI: 10.1016/j.jiac.2020.04.007.
39. Jackson D. J., Busse W. W., Bacharier L. B. et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 recepto2r ACE2 // J. AllergyClin. Immunol. – 2020. – Vol. 46, № 1. – Р. 203-206.e3. DOI: 10.1016/j.jaci.2020.04.009.
40. Khan A., Misdary C., Yegya-Raman N. et al. Montelukast in hospitalized patients diagnosed with COVID-19 // Research Square. – 2020.DOI:10.21203/rs.3.rs-52430/v1.
41. Khan M., Khan M. N., Mustagir M. G. et al. Effects of pre-existing morbidities on occurrence of death among COVID-19 disease patients: a systematic review and meta-analysis // J. Global. Health. – 2020. – Vol. 10, № 2. – 020503.DOI:10.7189/jogh.10.020503.
42. Klimek L., Jutel M., Akdis C. et al. Handling of allergen immunotherapy in theCOVID-19 pandemic: an ARIA-EAACI statement // Allergy. – 2020. – Vol. 75,№ 7. – Р. 1546-1554. DOI: 10.1111/all.14336.
43. Konopka K. E., Wilson A., Myers J. L. Postmortem lung findings in a patient with asthma and coronavirus disease 2019 // Chest. – 2020. – Vol. 158, № 3. –Р. e99-e101. DOI: 10.1016/j.chest.2020.04.032.
44. Kumar K., Hinks T. S. C., Singanayagam A. Treatment of COVID-19-exacerbatedasthma: should systemic corticosteroids be used? // Am. J. Physiol. Lung. Cell. Mol. Physiol. – 2020. – Vol. 318, № 6. – Р. L1244-L1247. DOI:10.1152/ajplung.00144.2020.
45. Li X., Xu S., Yu M. et al. Risk factors for severity and mortality in adultCOVID-19 inpatients in Wuhan // J. Allergy Clin. Immunol. – 2020. – Vol. 146,№ 1. – Р. 110-118. DOI: 10.1016/j.jaci.2020.04.006.
46. Licskai C., Yang C. L., Ducharme F. M. et al. Addressing therapeutic questions to help Canadian physicians optimize asthma management for their patients during the COVID-19 pandemic // Can. J. Respir. Crit. Care Sleep. Med. –2020. – Vol. 4, № 2. – Р. 73-76. DOI: 10.1080/24745332.2020.1754027.
47. Lindsley A. W., Schwartz J. T., Rothenberg M. E. Eosinophil responses duringCOVID-19 infections and coronavirus vaccination // J. Allergy Clin. Immunol. –2020. – Vol. 146, № 1. ‒ Р. 1-7. DOI: 10.1016/j.jaci.2020.04.021.
48. Liu S., Zhi Y., Ying S. COVID-19 and asthma: reflection during the pandemic // Clin. Rev. Allergy Immunol. – 2020. – Vol. 59, № 1. – Р. 78-88.DOI: 10.1007/s12016-020-08797-3.
49. Matsuyama S., Kawase M., Nao N. et al. The inhaled corticosteroid cicles on ide blocks coronavirus RNA replication by targeting viral NSP15 // BioRxiv. – 2020.DOI:10.1101/2020.03.11.987016.
50. Pennington E. Asthma increases risk of severity of COVID-19 // Cleve Clin. J.Med. ‒ 2020. DOI:10.3949/ccjm.87a.ccc002.
51. Peters M. C., Sajuthi S., Deford P. et al. COVID-19-related genesin sputum cells in asthma. Relationship to demographic features and corticosteroids // Am. J. Respir. Crit. Care Med. – 2020. – Vol. 202, № 1. –Р. 83-90. DOI: 10.1164/rccm.202003-0821OC.
52. Riggioni C., Comberiati P., Giovannini M. et al. A compendium answering150 questions on COVID-19 and SARS-CoV-2 // Allergy. – 2020. – Vol. 75,№ 5. – Р. 2503-2543. DOI: 10.1111/all.14449.
53. Sajuthi S. P., DeFord P., Jackson N. D. et al. Type 2 and interferon inflammation strongly regulate SARS-CoV-2 related gene expression in the airway epithelium // Biorxiv. – 2020. DOI: 10.1038/s41467-020-18781-2.
54. Schleicher G. K., Lowman W., Richards G. A. Case study: a patient with asthma, Covid-19 pneumonia and cytokine release syndrome treated with corticosteroids and tocilizumab // Wits J. Clin. Med. – 2020.– № 2 (SI). ‒ P. 47-52.
55. Shamsievna R. G. Modern Aspects of Studying the Features of Morph functional Characteristics of Testes Under Various Factor Influences //Eurasian Scientific Herald. – 2022. – Т. 7. – С. 279-286.
56. Starshinova A., Malkova A., Zinchenko U., Kudlay D., Glushkova A.,Dovgalyk I., Yablonskiy P., Shoenfeld Y. Efficacy of different types of therapy forCOVID-19: A comprehensive review // Life. ‒ 2021.‒ № 11.‒ Р. 753.https://doi.org/10.3390/life11080753.
57. Vultaggio A., Agache I., Akdis C. A. et al. Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: an EAACI statement //Allergy. – 2020. – Vol. 75, № 11. – Р. 2764-2774. DOI: 10.1111/all.14407.
58. Wan G.-H., Tsai Y.-H., Wu Y.-K., Tsao K.-C. A large-volume nebulizer would notbe an infectious source for severe acute respiratory syndrome // Infect. Control.ospEpidemiol. – 2004. – Vol. 25, № 12. – Р. 1113-1115. DOI: 10.1086/502353.
59. Wang D., Hu B., Hu C. et al. Clinical characteristics of 138 hospitalized patientswith 2019 novel coronavirus-infected pneumonia in Wuhan, China // JAMA. –2020. – Vol. 323, № 11. – Р.1061-1069. DOI: 10.1001/jama.2020.1585.
60. Wang Y., Jiang W., He Q. et al. Early, low-dose and short-term applicationof corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China // medRxiv. – 2020. DOI:10.1101/2020.03.06.20032342.
61. Yamaya M., Nishimura H., Deng X. et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication andcytokine production by primary cultures of human nasal and tracheal epithelialcells // Respir. Investig. – 2020. – Vol. 58, № 3. – Р. 155-168. DOI: 10.1016/j.resinv.2019.12.005.
62. Zhang J. J., Cao Y. Y., Dong X. et al. Distinct characteristics of COVID-19 patientswith initial rRT-PCR-positive and rRT-PCR-negative results for SARS-CoV-2 //Allergy. – 2020. – Vol. 75, № 7. – Р. 1809-1812. DOI: 10.1111/all.14316.
63. Zhang J. J., Dong X., Cao Y. Y. et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China // Allergy. – 2020. – Vol. 75,№ 7. – Р. 1730-1741. DOI:10.1111/all.14238.
64. Zhang W., Lin C., Sampath V., Nadeau K. Impact of allergen immunotherapy in allergic asthma // Immunotherapy. – 2018. – Vol. 10, № 7. – Р. 579-593. DOI:10.2217/imt-2017-0138.
65. Zhu Z., Hasegawa K., Ma B. et al. Association of asthma and its genetic predisposition with the risk of severe COVID-19 // J. Allergy Clin. Immunol. –2020. – Vol. 146, № 2. – Р. 327-329.e4. DOI: 10.1016/j.jaci.2020.06.001.
Published
2022-06-07
How to Cite
M. A., N., & O’. O, N. (2022). Covid-19 and Bronchial Asthma (Clinical and Epidemiological Aspects). Central Asian Journal of Medical and Natural Science, 3(3), 353-361. https://doi.org/10.17605/cajmns.v3i3.794
Section
Articles